Patents Represented by Attorney, Agent or Law Firm Nicole M. Wallinger
  • Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
    Patent number: 6638920
    Abstract: The present invention relates to compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses. The present invention further relates to compositions and methods for alleviating pain associated with skeletal injuries in horses and to treating skeletal injuries in horses.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: October 28, 2003
    Assignee: Merck & Co., Inc.
    Inventor: Donald R. Thompson
  • Compounds and compositions as protease inhibitors
    Patent number: 6525036
    Abstract: The present invention relates to novel cysteine protease inhibitors of Formula I: the pharmaceutically acceptable salts and N-oxide derivatives thereof, their use as therapeutic agents and methods of making them.
    Type: Grant
    Filed: January 5, 2001
    Date of Patent: February 25, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Renata Marcella Oballa, Petpiboon Prasit, Joel Stephane Robichaud, Elise Isabel, Eduardo Setti, Dan-Xiong Wang, Rohan V. Mendonca, Shankar Venkatraman
  • NPY Y5 receptor antagonists
    Patent number: 6495559
    Abstract: Compounds of general structural formula I such as that shown in structural formula II are selective NPY Y5 receptor antagonists, useful in the treatment of obesity and the complications associated therewith.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: December 17, 2002
    Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.
    Inventors: Ying-Duo Gao, Douglas J. MacNeil, Lihu Yang, Nancy R. Morin, Takehiro Fukami, Akio Kanatani, Takahiro Fukuroda, Yasuyuki Ishii, Masaki Ihara
  • Estrogen receptor
    Patent number: 6458551
    Abstract: This invention relates to a novel estrogen receptor and to the polynucleotide sequences encoding this receptor. This invention also relates to methods for identifying ligands which bind to this receptor, to the ligands so identified, and to pharmaceutical compositions comprising such ligands. This invention also relates to pharmaceutical compositions useful for treating or preventing estrogen receptor mediated diseases or conditions, such as abnormal bone resorption, cardiovascular diseases, cancer, or central nervous system disorders.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: October 1, 2002
    Assignee: Merck & Co., Inc.
    Inventor: Hilary Wilkinson
  • Methods of identifying modulators of kinases responsive to stress
    Patent number: 6416964
    Abstract: The present invention relates to methods of identifying compounds useful as modulators of certain stress responsive kinases. More particularly, the compounds so identified are useful for treating or preventing diseases or conditions that are mediated by, for example, abnormal bone resorption or angiogenesis. These compounds are useful for treating or preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, and tumor growth.
    Type: Grant
    Filed: January 27, 1999
    Date of Patent: July 9, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Alfred A. Reszka, Gideon A. Rodan
  • Methods for inhibiting bone resorption
    Patent number: 6414006
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: July 2, 2002
    Assignees: Merck Frosst Canada & Co., Merck & Co., Inc.
    Inventors: Shun-ichi Harada, Gideon A. Rodan, Mohamed Machwate, Marc LaBelle, Kathleen Metters, Robert N. Young
  • Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
    Patent number: 6399592
    Abstract: Disclosed is a combination therapy for treating and for preventing bone loss by the use of estrogen and a bisphosphonate selected from: alendronate, clodronate, tiludronate, YM175, BM 210995, or mixture thereof. Also described is a pharmaceutical composition of the above for carrying out the therapeutic method.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: June 4, 2002
    Assignee: Merck & Co., Inc.
    Inventor: Donna T. Whiteford
  • Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
    Patent number: 6376477
    Abstract: The inhibition of natural bone formation experienced in the prophylaxis and/or treatment of bone resorption disease with a bisphosphonic acid or a pharmaceutically acceptable salt thereof is overcome by the concommitant administration of an agent that binds to the androgen receptor.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: April 23, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Azriel Schmidt, Shun-Ichi Harada, Gideon Rodan
  • Whole cell assay for cathepsin K activity
    Patent number: 6346373
    Abstract: The present invention relates to a whole cell assay for cathepsin K. The present invention is useful for determining cathepsin K activity in a mammalian cell systems and for identifying and evaluating inhibitors of cathepsin K.
    Type: Grant
    Filed: April 20, 2000
    Date of Patent: February 12, 2002
    Assignee: Merck Frosst Canada & Co.,
    Inventors: Joseph Mancini, Denis Riendeau, David Claveau
  • Method for inhibiting dental resorptive lesions
    Patent number: 6331533
    Abstract: The present invention relates to a method for inhibiting dental resorptive lesions and other disease states associated with dental resorptive lesions in a mammal by administering a therapeutically effective amount of a bisphosphonate or a pharmaceutically acceptable salt thereof to a mammal in need thereof. This invention also relates methods of alleviating of pain and reducing the risk of tooth loss associated with dental resorptive lesions in mammals.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: December 18, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Colin E. Harvey, Kenneth L. Mohn
  • Spiro-indolines as Y5 receptor antagonists
    Patent number: 6313298
    Abstract: Compounds of general structural formula I such as that shown in structural formula II are selective NPY Y5 receptor antagonists, useful in the treatment of obesity and the complications associated therewith.
    Type: Grant
    Filed: September 7, 2000
    Date of Patent: November 6, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Ying-Duo Gao, Lihu Yang, Douglas J. MacNeil, Nancy R. Morin, Takehiro Fukami, Takahiro Fukuroda, Akio Kanatani, Yasuyuki Ishii, Masaki Ihara
  • Spiro-indolines as Y5 receptor antagonists
    Patent number: 6191160
    Abstract: Compounds of the general structural formula I are selective NPY Y5 receptor antagonists. The compounds and compositions of the present invention are useful in the treatment of obesity and complications associated therewith.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: February 20, 2001
    Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.
    Inventors: Ying-Duo Gao, Douglas J. MacNeil, Lihu Yang, Nancy R. Morin, Takehiro Fukami, Akio Kanatani, Takahiro Fukuroda, Yasuyuki Ishii, Masaki Ihara